Compounds of the formula (I), or a pharmaceutically-acceptable salt, or an in-vivo-hydrolysable ester thereof, (I) R1a is NH(C═W)R5 or (a); W is O or S; R2 and R3 are for example H or F; R1 is for example hydrogen, or halogen; R5 is selected from hydrogen, (2–6C)alkyl (optionally substituted); R6 and R7 are independently selected from hydrogen, and (1–4C)alkyl (optionally substituted); wherein R4 is either a hydroxymethyl substituent on C-4′ of the isoxazoline ring; or R4 is a hydroxymethyl substituent on C-5′ of the isoxazoline ring and the stereochemistry at C-5′ of the isoxazoline ring and at C-5 of the oxazolidinone ring is selected, such that the compound of formula (I) is a single diastereomer; are useful as antibacterial agents; and processes for their manufacture and pharmaceutical compositions containing them are described
公式(I)的化合物,或其药学上可接受的盐,或其体内
水解酯,其中(I)R1a为NH(C═W)R5或(a); W为O或S; R2和R3例如为H或F; R1例如为氢或卤素; R5选择自氢,(2-6C)烷基(可选取代); R6和R7独立选择自氢和(1-4C)烷基(可选取代);其中R4是位于
异噁唑烷环的C-4'上的羟甲基取代基;或R4是位于
异噁唑烷环的C-5'上的羟甲基取代基,并且
异噁唑烷环的C-5'和
噁唑烷酮环的C-5的立体
化学被选择,以使公式(I)的化合物为单一对映体; 适用于抗菌剂;并描述了它们的制造过程和含有它们的药物组合物。